Vincerx Pharma Inc [NASDAQ: VINC] closed the trading session at $0.70.
The stocks have a year to date performance of -40.85 percent and weekly performance of -2.51 percent. The stock has been moved at -85.40 percent over the last six months. The stock has performed -2.24 percent around the most recent 30 days and changed 1.19 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 164.50K shares, VINC reached to a volume of 4658293 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Vincerx Pharma Inc [VINC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VINC shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VINC stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Vincerx Pharma Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 14, 2022. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on December 23, 2021, representing the official price target for Vincerx Pharma Inc stock. Previously, the target price had yet another raise to $24, while SVB Leerink analysts kept a Outperform rating on VINC stock.
The Average True Range (ATR) for Vincerx Pharma Inc is set at 0.06 The Price to Book ratio for the last quarter was 1.34, with the Price to Cash per share for the same quarter was set at 0.53.
VINC stock trade performance evaluation
Vincerx Pharma Inc [VINC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.51. With this latest performance, VINC shares dropped by -2.24% in over the last four-week period, additionally sinking by -85.40% over the last 6 months – not to mention a drop of -29.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VINC stock in for the last two-week period is set at 48.26, with the RSI for the last a single of trading hit 46.95, and the three-weeks RSI is set at 48.57 for Vincerx Pharma Inc [VINC]. The present Moving Average for the last 50 days of trading for this stock 0.6875, while it was recorded at 0.7044 for the last single week of trading, and 1.6281 for the last 200 days.
Vincerx Pharma Inc [VINC]: An insightful look at the core fundamentals
Vincerx Pharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.43 and a Current Ratio set at 3.43.
Earnings per share (EPS) analysis for Vincerx Pharma Inc [VINC] stock
With the latest financial reports released by the company, Vincerx Pharma Inc posted -0.46/share EPS, while the average EPS was predicted by analysts to be reported at -0.46/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VINC.
Vincerx Pharma Inc [VINC]: Institutional Ownership
There are presently around $36.16%, or 44.13%% of VINC stock, in the hands of institutional investors. The top three institutional holders of VINC stocks are: PROSIGHT MANAGEMENT, LP with ownership of 2.49 million shares, which is approximately 11.6281%. ARMISTICE CAPITAL, LLC, holding 1.99 million shares of the stock with an approximate value of $$1.61 million in VINC stocks shares; and ARMISTICE CAPITAL, LLC, currently with $$1.38 million in VINC stock with ownership which is approximately 7.9599%.
